Jon Keidan
Founder & Managing Partner @ Torch Capital
New York, United States
Jon Keidan is a seed investor at Torch Capital in New York focused on Food and Beverage and E-Commerce. Jonathan is the Founder of Torch Capital. A long time entrepreneur and investor, he has spent his career at the intersection of the media, technology and entertainment industries. He is the Co-Founder of digital media company InsideHook and has spent a decade as an active early stage investor and advisor to a number of New York and LA's topstart-ups.
- Total investments:
- 72
- Last investment:
- Lead investor:
- 3%
Last updated:
For AI agents: llms.txt
Industries Jon Keidan invests in
Stages Jon Keidan invests in
Countries Jon Keidan invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1M–$8M
- Series A
- $3M–$30M
- Series B
- $15M–$85M
Investment Focus
Industry
- Food and Beverage 10 (14%)
- E-Commerce 9 (13%)
- Internet 7 (10%)
- Software 7 (10%)
- Health Care 7 (10%)
Stage
- Seed 25 (35%)
- Series A 15 (21%)
- Series B 6 (8%)
- Series C 4 (6%)
- Funding Round 4 (6%)
Country
- United States 44 (61%)
- Canada 1 (1%)
- Germany 1 (1%)
- Vietnam 1 (1%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Salvo is emerging as the leader in helping GI providers leap into a hybrid-care vision of the future of medicine, providing brick & mortar clinics with an easy to implement continuous care platform that saves time, increases revenue and improves patient outcomes.The company has announced agreements with 771 GI’s, representing 15% of allindependent GI’s in the US, to deploy wraparound care for their clinic patients. Included in its customers are five of the largest GI practices in the country, together seeing over 1.1 million GI patients a year. Salvo provides the tech and care delivery for modern, interdisciplinary care to treat chronic conditions that have surged in cost and prevalence: --IBS and IBD (over 40M affected) -- GERD and Celiac (over 50M affected) --MASH/MASLD, what was previously called “fatty liver disease” (over 80M) --Obesity (over 100M) The care benefits patients (76% of patients reported improved symptoms, five accepted medical conference abstracts on outcomes), generates incremental profit for practices (over $2M EBITDA improvement for a 100 GI practice), and reduces total healthcare costs (79% drop in GI-related ER utilization). | $8.5M / Series A / Jan 22, 2026 | ||
| Arcade is a B2C platform that transforms the jewelry market through its prompt-to-product solution, allowing users to create unique designs using AI. The marketplace supports various user roles, enabling customers, designers, and influencers to engage and collaborate. | $25M / Series A / Mar 24, 2025 | ||
| Little Otter is a children's mental health company that developed an app that focuses on the mental health of children and their families. Little Otter is a family-focused mental health service for children. The company app makes it simple to connect with qualified providers from the convenience of the user's phone and gain access toadvice and guidance developed by Dr. Helen Egger and child mental health experts. | $9.5M / Feb 05, 2025 | ||
| Sollis Health, formerly known as Priority Private Care (PPC), offers members access to medical facilities, including best-in-class ER physicians who manage their care from check-in to follow-up, superior staff to attend to a member’s every need, advanced diagnostic imaging, VIP support from leading hospitals, and fast access to our hand-selectedspecialist network. The company specializes in concierge urgent and emergency care, functioning similarly to having a personal doctor available at all times. | $33M / Series B / Dec 05, 2024 | ||
| Sollis Health, formerly known as Priority Private Care (PPC), offers members access to medical facilities, including best-in-class ER physicians who manage their care from check-in to follow-up, superior staff to attend to a member’s every need, advanced diagnostic imaging, VIP support from leading hospitals, and fast access to our hand-selectedspecialist network. The company specializes in concierge urgent and emergency care, functioning similarly to having a personal doctor available at all times. | $15M / Series A / Jun 21, 2023 | ||
| Salvo is emerging as the leader in helping GI providers leap into a hybrid-care vision of the future of medicine, providing brick & mortar clinics with an easy to implement continuous care platform that saves time, increases revenue and improves patient outcomes.The company has announced agreements with 771 GI’s, representing 15% of allindependent GI’s in the US, to deploy wraparound care for their clinic patients. Included in its customers are five of the largest GI practices in the country, together seeing over 1.1 million GI patients a year. Salvo provides the tech and care delivery for modern, interdisciplinary care to treat chronic conditions that have surged in cost and prevalence: --IBS and IBD (over 40M affected) -- GERD and Celiac (over 50M affected) --MASH/MASLD, what was previously called “fatty liver disease” (over 80M) --Obesity (over 100M) The care benefits patients (76% of patients reported improved symptoms, five accepted medical conference abstracts on outcomes), generates incremental profit for practices (over $2M EBITDA improvement for a 100 GI practice), and reduces total healthcare costs (79% drop in GI-related ER utilization). | $10.5M / Seed / Aug 05, 2022 | ||
| Sollis Health, formerly known as Priority Private Care (PPC), offers members access to medical facilities, including best-in-class ER physicians who manage their care from check-in to follow-up, superior staff to attend to a member’s every need, advanced diagnostic imaging, VIP support from leading hospitals, and fast access to our hand-selectedspecialist network. The company specializes in concierge urgent and emergency care, functioning similarly to having a personal doctor available at all times. | $30M / Series A / Jan 21, 2022 | ||
| Little Otter is a children's mental health company that developed an app that focuses on the mental health of children and their families. Little Otter is a family-focused mental health service for children. The company app makes it simple to connect with qualified providers from the convenience of the user's phone and gain access toadvice and guidance developed by Dr. Helen Egger and child mental health experts. | $22M / Series A / Jan 06, 2022 | ||
| Jane Technologies is a cannabis retail tech company that provides its consumers with a confident, safe and simple shopping experience. Users can browse local products in real-time, compare by price, proximity or popularity and place orders at local stores for free. Jane partners with dispensaries on a win-win basis; stores only pay for completedorders at a fraction of the price of other industry software. | $100M / Series C / Aug 25, 2021 | ||
| Lobos 1707 Tequila is an independent spirits producer. It specializes in the fields of retail, manufacturing and distribution of wine and spirits. | Series D / Jul 22, 2021 | ||
| See all 72 investments → | |||
Co-Investors
About Torch Capital
Torch Capital is an early-stage venture fund investing in consumer technology companies and the infrastructure layers that power them
Torch Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Christopher Harper
Principal
|
|||
Curtis Cheng
Investor
|
|||
|
Jon Keidan
Founder & Managing Partner
|
|||
Katie Reiner
Principal
|
|||
Sam Jones
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Jon Keidan invest in?
Jon Keidan invests primarily in Food and Beverage, E-Commerce and Internet startups, most often at Seed and Series A stage. Most of the 72 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Jon Keidan's check size?
Jon Keidan typically joins rounds of $1M–$8M at Seed, $3M–$30M at Series A and $15M–$85M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Jon Keidan participates in.
How do I contact Jon Keidan?
Public channels for Jon Keidan include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jon Keidan last invest?
The most recent investment recorded for Jon Keidan closed in Jan 2026. Shizune tracks 72 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
